Novo Nordisk Stock: A Rare Buying Opportunity
分组1 - Novo Nordisk A/S (NVO) experienced a decline of approximately 16% in pre-market trading following disappointing trial results for its obesity drug, CagriSema [2]
分组1 - Novo Nordisk A/S (NVO) experienced a decline of approximately 16% in pre-market trading following disappointing trial results for its obesity drug, CagriSema [2]